Oncology Xagena
A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow de ...
Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-val ...
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...
Older and younger patients with renal cancer derive similar benefit from Sorafenib ( Nexavar ) therapy and tolerate the drug equally well. Although the risk of being diagnosed with cancer increa ...
European Researchers have found that metastatic colorectal cancer patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with Cetuximab ( Erbitux ) and Panitumumab ( Vectibix ...
Treatment with Everolimus ( Certican ) prolongs progression-free survival relative to placebo in patients with metastatic kidney cancer ( renal cell carcinoma ) who have experienced treatment failur ...
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...
In the advanced breast cancer, one study has found that if Sorafenib ( Nexavar ) is combined with the chemotherapy drug, Capecitabine ( Xeloda ), it makes a significant difference to the time women li ...
The cancer drug Sorafenib ( Nexavar ) holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial.If approved for use in thyroid ...
Bayer HealthCare and Onyx Pharmaceuticals, have announced that the FDA ( Food and Drug Administration ) has approved the oral multi-kinase inhibitor Nexavar ( Sorafenib ) for the treatment of patients ...
An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor ( FGF ) pathway activation ha ...
Hepatocellular carcinoma ( HCC ) is responsible for over 600,000 deaths annually. In addition, hepatocellular carcinoma is characterized by its propensity to invade the liver vasculature. Macrovascu ...
Radical metastasectomy followed by observation is a commonly used strategy in selected patients with metastatic renal cell carcinoma ( mRCC ). RESORT was the largest prospective study that assesse ...
Sorafenib ( Nexavar ) is approved as first-line therapy for patients with advanced hepatocellular carcinoma ( HCC ), but there is still an unmet need to prolong survival and improve tolerability. A ...
Results from the phase III IMbrave150 study evaluating Atezolizumab ( Tecentriq ) in combination with Bevacizumab ( Avastin ) were presented. The data have shown statistically significant and clinic ...
